

Special Issue

Study Designs and Quantitative Tools in Rare and Life-Threatening Brain Tumor

Message from the Guest Editor

Glioblastoma is a rare, life-threatening, and highly difficult to cure disease. It has shown high failure in phase 3 glioblastoma trials, even though previous phase 2 trials showed promising efficacy. There may be a need for earlier studies to become more reliable and for the use of evidence-based quantitative tools to overcome the disconnection from phase 2 to phase 3 trials. This disconnection could be occurring for several reasons: design restriction of preclinical studies and differences between animals and human, traditional single-arm trials in phase 2 trials in GBM, and the surrogate of progression-free survival of phase 2 trials for overall survival in phase 3 trials. With the recent advancements in technology and programming languages, we are able to utilize these new technologies to develop novel study designs using quantitative tools.

Guest Editor

Dr. Wonsuk Yoo
Ivy Brain Tumor Center, Phoenix, AZ 85013, USA

Deadline for manuscript submissions

closed (20 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/195896

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)